Cargando…

Novel anti-melanoma treatment: focus on immunotherapy

Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Meng-Ze, Zhou, Wen-Ya, Du, Xiao-Ling, Chen, Ke-Xin, Wang, Guo-Wen, Yang, Yun, Yang, Ji-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190435/
https://www.ncbi.nlm.nih.gov/pubmed/25189718
http://dx.doi.org/10.5732/cjc.014.10118
_version_ 1782338510375616512
author Hao, Meng-Ze
Zhou, Wen-Ya
Du, Xiao-Ling
Chen, Ke-Xin
Wang, Guo-Wen
Yang, Yun
Yang, Ji-Long
author_facet Hao, Meng-Ze
Zhou, Wen-Ya
Du, Xiao-Ling
Chen, Ke-Xin
Wang, Guo-Wen
Yang, Yun
Yang, Ji-Long
author_sort Hao, Meng-Ze
collection PubMed
description Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma.
format Online
Article
Text
id pubmed-4190435
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Sun Yat-sen University Cancer Center
record_format MEDLINE/PubMed
spelling pubmed-41904352014-10-15 Novel anti-melanoma treatment: focus on immunotherapy Hao, Meng-Ze Zhou, Wen-Ya Du, Xiao-Ling Chen, Ke-Xin Wang, Guo-Wen Yang, Yun Yang, Ji-Long Chin J Cancer Review Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma. Sun Yat-sen University Cancer Center 2014-09 /pmc/articles/PMC4190435/ /pubmed/25189718 http://dx.doi.org/10.5732/cjc.014.10118 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission.
spellingShingle Review
Hao, Meng-Ze
Zhou, Wen-Ya
Du, Xiao-Ling
Chen, Ke-Xin
Wang, Guo-Wen
Yang, Yun
Yang, Ji-Long
Novel anti-melanoma treatment: focus on immunotherapy
title Novel anti-melanoma treatment: focus on immunotherapy
title_full Novel anti-melanoma treatment: focus on immunotherapy
title_fullStr Novel anti-melanoma treatment: focus on immunotherapy
title_full_unstemmed Novel anti-melanoma treatment: focus on immunotherapy
title_short Novel anti-melanoma treatment: focus on immunotherapy
title_sort novel anti-melanoma treatment: focus on immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190435/
https://www.ncbi.nlm.nih.gov/pubmed/25189718
http://dx.doi.org/10.5732/cjc.014.10118
work_keys_str_mv AT haomengze novelantimelanomatreatmentfocusonimmunotherapy
AT zhouwenya novelantimelanomatreatmentfocusonimmunotherapy
AT duxiaoling novelantimelanomatreatmentfocusonimmunotherapy
AT chenkexin novelantimelanomatreatmentfocusonimmunotherapy
AT wangguowen novelantimelanomatreatmentfocusonimmunotherapy
AT yangyun novelantimelanomatreatmentfocusonimmunotherapy
AT yangjilong novelantimelanomatreatmentfocusonimmunotherapy